IN2014CN02850A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02850A
IN2014CN02850A IN2850CHN2014A IN2014CN02850A IN 2014CN02850 A IN2014CN02850 A IN 2014CN02850A IN 2850CHN2014 A IN2850CHN2014 A IN 2850CHN2014A IN 2014CN02850 A IN2014CN02850 A IN 2014CN02850A
Authority
IN
India
Prior art keywords
methylbenzenesulfonamide
indazol
reconstitution
pyrimidinyl
methylamino
Prior art date
Application number
Other languages
English (en)
Inventor
Augustus Campbell Gossett
Helen Richardson
Peter A Williams
Original Assignee
Glaxosmithkline Intellectual Property Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Ltd filed Critical Glaxosmithkline Intellectual Property Ltd
Publication of IN2014CN02850A publication Critical patent/IN2014CN02850A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2850CHN2014 2011-10-31 2012-10-16 IN2014CN02850A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553454P 2011-10-31 2011-10-31
PCT/US2012/060361 WO2013066616A1 (fr) 2011-10-31 2012-10-16 Formulation de pazopanib

Publications (1)

Publication Number Publication Date
IN2014CN02850A true IN2014CN02850A (fr) 2015-07-03

Family

ID=48192602

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2850CHN2014 IN2014CN02850A (fr) 2011-10-31 2012-10-16

Country Status (12)

Country Link
US (3) US9278099B2 (fr)
EP (1) EP2773204A4 (fr)
JP (2) JP6200893B2 (fr)
KR (1) KR101993436B1 (fr)
CN (1) CN104254249B (fr)
AU (1) AU2012332952B2 (fr)
BR (1) BR112014010551A2 (fr)
CA (1) CA2852912A1 (fr)
HK (1) HK1201685A1 (fr)
IN (1) IN2014CN02850A (fr)
RU (1) RU2616500C2 (fr)
WO (1) WO2013066616A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015145157A1 (fr) * 2014-03-28 2015-10-01 Cipla Limited Composition pharmaceutique contenant du pazopanib
CA3060247A1 (fr) 2017-04-17 2018-10-25 Yale University Composes, compositions et methodes de traitement ou de prevention d'une lesion pulmonaire aigue
WO2019053500A1 (fr) 2018-04-17 2019-03-21 Alvogen Malta Operations (Row) Ltd Composition pharmaceutique de forme posologique solide contenant du pazopanib et son procédé de préparation
CN112236146A (zh) 2018-04-24 2021-01-15 盐野义制药株式会社 稳定性优良的固体制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH675537A5 (fr) 1988-03-25 1990-10-15 Ciba Geigy Ag
ATE87476T1 (de) 1988-11-10 1993-04-15 Ciba Geigy Ag Fluessige orale formulierung.
WO2002059110A1 (fr) * 2000-12-21 2002-08-01 Glaxo Group Limited Composes chimiques
CZ12993U1 (cs) * 2001-11-23 2003-02-10 Glaxo Group Limited Farmaceutický prostředek
RU2255730C1 (ru) * 2003-10-14 2005-07-10 Федеральное государственное унитарное предприятие "Всероссийкий научный центр по безопасности биологически активных веществ" (ФГУП "ВНЦ БАВ") Стабильная фармацевтическая суспензия азитромицина и способ ее получения
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
DK1954281T3 (da) * 2005-11-29 2011-05-16 Glaxosmithkline Llc Fremgangsmåde til cancerbehandling
CA2631173A1 (fr) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Procede de traitement
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
US20100267787A1 (en) * 2007-11-12 2010-10-21 Gregory Harasymiw Pharmaceutical Compositions
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
WO2009128932A1 (fr) * 2008-04-15 2009-10-22 Sarcode Corporation Administration d'antagonistes de lfa-1 au système gastro-intestinal
US20100221247A1 (en) * 2008-09-29 2010-09-02 Robert Bender Agents and methods for treatment of cancer
US20100291025A1 (en) * 2009-04-13 2010-11-18 Auspex Pharmaceuticals, Inc. Indazole inhibitors of tyrosine kinase
EP2298321A1 (fr) * 2009-08-26 2011-03-23 Nordic Pharma Nouvelles compositions pharmaceutiques pour le traitement de maladies intestinales inflammatoires
US8501811B2 (en) * 2010-06-17 2013-08-06 Washington University TASPASE1 inhibitors and their uses

Also Published As

Publication number Publication date
CN104254249A (zh) 2014-12-31
JP6200893B2 (ja) 2017-09-20
CA2852912A1 (fr) 2013-05-10
AU2012332952A1 (en) 2014-05-15
BR112014010551A2 (pt) 2017-05-02
HK1201685A1 (en) 2015-09-11
RU2616500C2 (ru) 2017-04-17
RU2014115289A (ru) 2015-12-10
JP2014534215A (ja) 2014-12-18
AU2012332952B2 (en) 2016-05-05
US10080802B2 (en) 2018-09-25
US10596263B2 (en) 2020-03-24
US20140255505A1 (en) 2014-09-11
CN104254249B (zh) 2017-02-15
KR101993436B1 (ko) 2019-06-26
US9278099B2 (en) 2016-03-08
JP6423484B2 (ja) 2018-11-14
US20160120988A1 (en) 2016-05-05
EP2773204A1 (fr) 2014-09-10
KR20140096082A (ko) 2014-08-04
JP2017197542A (ja) 2017-11-02
US20180360971A1 (en) 2018-12-20
WO2013066616A1 (fr) 2013-05-10
EP2773204A4 (fr) 2015-05-27

Similar Documents

Publication Publication Date Title
PH12016501535A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
BR112012031297A2 (pt) formulações de spray oral e métodos para administração de sildenafil
MX2013001677A (es) Formulaciones estables de linaclotida.
EA201291348A1 (ru) Активаторы растворимой гуанилатциклазы
SG10201804817TA (en) Delayed release compositions of linaclotide
MD20150050A2 (ro) Soluţii midriatice şi antiinflamatorii stabile fără conservanţi pentru injectare
RS53898B1 (en) QUINAZOLINE-4 (3H) -ONE DERIVATIVES USED AS PI3 KINASE INHIBITORS
SG11201502622VA (en) PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
MX360634B (es) Inhibidores de 3-haloalilamina sustituidos de ssao y uso de los mismos.
GEP201706774B (en) Heterocyclyl compounds
MX357043B (es) Inhibidores selectivos de pi3k delta.
MX358172B (es) Derivados de pirazol aminopirimidina como moduladores de la proteina cinasa 2 de repeticion rica en leucina (lrrk2) para usarse en el tratamiento de la enfermedad de parkinson.
MX2014006026A (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX348606B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2).
IL217052A0 (en) Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
NZ707160A (en) A stable aqueous composition comprising human insulin or an analogue or derivative thereof
MX2013010046A (es) Administracion parenteral de tapentadol.
UA116875C2 (uk) Поліморфи arry-380 селективного інгібітору erbb2 і фармацевтичні композиції, що їх містять
IN2014CN02850A (fr)
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
MY186698A (en) Solid forms of ceftolozane
PH12016500322A1 (en) Amide derivatives as lysophosphatidic acid receptor antagonists
MX2014013664A (es) N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida.
TN2012000105A1 (en) Spirolactam derivatives and uses of same
GEP20146182B (en) Delta crystalline form of arginine salt of perindopril, process for its preparation, and pharmaceutical com¬po¬- sitions containing it